Philippe Ledru - 13 Apr 2022 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role
Chief Commercial Officer
Signature
/s/ Janet Clennett as attorney-in-fact for Philippe Ledru
Issuer symbol
APTOF
Transactions as of
13 Apr 2022
Net transactions value
$0
Form type
4
Filing time
14 Apr 2022, 20:59:12 UTC
Previous filing
14 Apr 2022
Next filing
23 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APTO Employee Stock Option Award $0 +600,000 $0.000000 600,000 13 Apr 2022 Common Shares 600,000 $1.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fifty percent (50%) of the shares vest on 4/13/2023; the remaining 50% vest as follows: 1/3 on 4/13/2024; 1/3 on 4/13/2025; and 1/3 on 4/13/2026.